Healthcare / BiotechnologyNasdaqGS
$29.86
-0.63 (-2.07%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $31.1M · quality 52.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
69/100
B
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$552M
P/E
1.5x
↓EV/EBITDA
4.4x
↓ROE
93.8%
↑Gross Margin
93.3%
↑Debt/Equity
0.14
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
25.7%
FCF / Net income
0.21x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $294.3M · net income $367.0M · FCF $75.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $294.3M | $294.3M | $179.3M | $116.9M | $120.2M | $149.2M | $108.6M | $59.3M | $44.5M | $4.5M | $20.4M | — | — | — | — | — | — | — |
| Net Income | $367.0M | $367.0M | $17.5M | $-25.1M | $-58.6M | $-17.9M | $-29.7M | $-66.9M | $-70.5M | $-78.0M | $-69.2M | $-51.5M | $-90.9M | $-89.0M | $-98.8M | $-86.0M | $37.9M | $-111.5M |
| EBITDA | $131.6M | $131.6M | $28.5M | $-17.0M | $-53.9M | $-11.3M | $-28.3M | $-68.4M | $-72.1M | $-79.2M | $-68.8M | $-50.3M | $-88.9M | $-86.9M | $-96.9M | $-84.4M | $36.6M | $-110.6M |
| EPS | 19.48 | 19.48 | 0.99 | -1.44 | -3.40 | -1.10 | -1.80 | -4.00 | — | — | — | — | — | — | -13.20 | -13.60 | 7.20 | -27.30 |
| Gross Margin | 93.3% | 93.3% | 89.6% | 93.9% | 98.5% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | 42.6% | 42.6% | 13.5% | -17.5% | -45.1% | -8.4% | -26.7% | -116.5% | -163.3% | -1775.6% | -342.2% | — | — | — | — | — | — | — |
| Net Margin | 124.7% | 124.7% | 9.8% | -21.5% | -48.7% | -12.0% | -27.4% | -112.8% | -158.3% | -1739.3% | -339.6% | — | — | — | — | — | — | — |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.14 | 0.14 | 18.24 | -2.11 | -3.05 | 0.66 | 0.59 | 0.19 | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 2.62 | 2.62 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $75.7M | $75.7M | $31.1M | $-20.7M | $-74.2M | $5.3M | $-53.4M | $-43.0M | $-59.9M | $-77.7M | $-76.7M | $-24.0M | — | — | — | — | — | — |
| Returns | ||||||||||||||||||
| ROE | 93.8% | 93.8% | 531.8% | 87.6% | 430.2% | -59.0% | -87.4% | -124.3% | -64.1% | -77.5% | -125.8% | -56.3% | -70.9% | -42.7% | -34.2% | -36.4% | 22.8% | -101.5% |
| Valuation | ||||||||||||||||||
| P/E | 1.55 | 1.55 | 17.56 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 4.37 | 4.37 | 10.89 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 1.44 | 1.44 | 93.49 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | 64.1% | 64.1% | 53.4% | -2.8% | — | 37.4% | 83.2% | 33.2% | 892.6% | -78.0% | — | — | — | — | — | — | — | — |
| EPS Growth | 1867.7% | 1867.7% | 168.7% | 57.6% | — | 38.9% | 55.0% | — | — | — | — | — | — | — | 2.9% | -288.9% | 126.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-48.6%
EPS terminal req.
$2.65
Spread vs growth
1916.2%
5Y implied EPS CAGR
-30.3%
EPS terminal req.
$3.21
Spread vs growth
1898.0%
10Y implied EPS CAGR
-12.4%
EPS terminal req.
$5.16
Spread vs growth
1880.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+55.5%
Start / end P/E
19.4x → 1.5x
EPS bridge
0.99 → 19.48
Residual
-1720.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.